- Report
- October 2023
- 77 Pages
Global
From €3500EUR$3,899USD£3,108GBP
- Report
- February 2022
- 71 Pages
Global
From €3200EUR$3,565USD£2,841GBP
- Report
- June 2023
- 110 Pages
Global
From €3500EUR$3,899USD£3,108GBP
- Report
- May 2022
- 36 Pages
Global
From €3365EUR$3,500USD£2,887GBP
- Report
- May 2022
- 45 Pages
Global
From €2404EUR$2,500USD£2,062GBP
- Report
- May 2022
- 37 Pages
Global
From €2404EUR$2,500USD£2,062GBP
- Report
- May 2022
- 43 Pages
Global
From €2404EUR$2,500USD£2,062GBP
- Report
- May 2022
- 38 Pages
Global
From €2404EUR$2,500USD£2,062GBP
- Report
- November 2021
- 747 Pages
Global
From €3846EUR$4,000USD£3,299GBP
- Report
- February 2024
- 180 Pages
Global
From €5288EUR$5,499USD£4,536GBP
- Report
- April 2023
- 160 Pages
Global
From €5768EUR$5,999USD£4,948GBP
Somatostatin is a peptide hormone that is used in the treatment of various types of cancer. It is used to inhibit the release of growth hormones, which can help reduce the size of tumors. It is also used to reduce the side effects of chemotherapy and radiation therapy. Somatostatin is available in both injectable and oral forms. It is often used in combination with other drugs to treat cancer.
Somatostatin is used to treat a variety of cancers, including pancreatic, prostate, and neuroendocrine tumors. It is also used to treat acromegaly, a condition caused by excessive growth hormone production. Somatostatin is also used to treat Cushing's syndrome, a condition caused by excessive cortisol production.
Some companies that produce somatostatin include Novartis, Merck, and Pfizer. Other companies that produce somatostatin-based drugs include Ipsen, Teva, and Sandoz. Show Less Read more